📘 Chapter 153 · Gender-Affirming Sex Hormone Therapy

Nelson Textbook of Pediatrics 22nd Edition | Estrogen (17β-estradiol) for transgender females, testosterone for transgender males, puberty induction protocols, monitoring, adverse effects (VTE, polycythemia, dyslipidemia), fertility preservation, WPATH SOC 8, Endocrine Society guidelines.

🌐 paeds.online — Pakistan's Pediatric Platform
🏳️‍⚧️ Hormone Therapy · Medically Necessary · Evidence-Based

📋 30 Clinical Scenarios — Gender-Affirming Sex Hormone Therapy (FCPS level)

📇 High‑Yield Review Cards (Gender-Affirming Hormone Therapy)

🩺 Clinical Scenarios: Hormone Therapy Management

Select a clinical scenario for management guidance.

📋 Stepwise Management: Gender-Affirming Hormone Therapy

MedicationRouteInitial Dose (Puberty induction)Adult DoseMonitoring
17β-estradiolOral/sublingual5 μg/kg/day2-6 mg/dayEstradiol, prolactin, VTE risk
17β-estradiolTransdermal6.25-12.5 μg/24h50-200 μg/24hEstradiol, skin reaction
Testosterone cypionate/enanthateIM/SubQ12.5 mg/m² weekly or 25 mg/m² q2wk30-100 mg weekly or 60-200 mg q2wkTestosterone, CBC, lipids

    ⚡ Reflex Prompts — Critical Hormone Therapy Decisions

    📖 Summary: Gender-Affirming Sex Hormone Therapy — Nelson 22nd Ed